NCT06879782

Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study on the Efficacy and Safety of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease.

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 820 (estimated)
• Sponsor: Lunan Better Pharmaceutical Co., LTD. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of Lifitegrast Ophthalmic Solution.

Conditions

• Dry Eye Disease (DED)

Interventions

Type	Name	Description
DRUG	Drug placebo	Instill one drop of the eye solution in each eye, twice a day (morning and evening, approximately 12 hours apart), for a treatment period of 12 weeks.

Timeline

• Start date: 2024-03-28
• Primary completion: 2026-03-28
• Completion: 2026-09-28
• First posted: 2025-03-17
• Last updated: 2025-03-17

Locations

1 site across 1 country: China